scholarly journals Comparison of the Incidence of Postoperative Hypothyroidism in Patients Undergoing Conventional Thyroid Lobectomy and Pyramid- and Isthmus-Preserving Lobectomy

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Min Jeong Cho ◽  
Hyeong Won Yu ◽  
Woochul Kim ◽  
Yeo Koon Kim ◽  
Sang Il Choi ◽  
...  
Keyword(s):  
Thyroid Stimulating Hormone ◽  
Thyroid Lobectomy ◽  
Significant Difference ◽  
Before And After ◽  
Pyramidal Lobe ◽  
Stimulating Hormone

Hypothyroidism is a recognized sequela of conventional thyroid lobectomy. However, there have been no studies on the incidence of hypothyroidism following the preservation of the isthmus and pyramid during lobectomy. Therefore, in the present study, we compared the incidence of hypothyroidism following conventional lobectomy and lobectomy during which the isthmus and pyramidal lobe were preserved. Data for a total of 65 patients collected between September 2018 and April 2019 were reviewed retrospectively. Circulating thyroid-stimulating hormone (TSH) concentration was measured before and after surgery in a group who underwent conventional thyroid lobectomy (n = 29) and in a group in which the isthmus and pyramid were preserved (n = 36). We found no significant difference in TSH concentration between the two groups before surgery, or 3 months or 1 year after surgery. Thus, there might be no difference in the incidence of postoperative hypothyroidism between patients who undergo conventional thyroid lobectomy and those in which the isthmus and pyramid are preserved.

Percentile transformation and recalibration functions allow harmonization of thyroid-stimulating hormone (TSH) immunoassay results

2020 ◽  
Vol 58 (10) ◽  
pp. 1663-1672 ◽  
Author(s):  
Andrea Padoan ◽  
Aldo Clerico ◽  
Martina Zaninotto ◽  
Tommaso Trenti ◽  
Renato Tozzoli ◽  
...  
Keyword(s):  
Robust Regression ◽  
Reference Intervals ◽  
Thyroid Stimulating Hormone ◽  
Validation Dataset ◽  
New Approach ◽  
Coefficients Of Variation ◽  
Significant Difference ◽  
Before And After ◽  
Roche Diagnostics ◽  
Stimulating Hormone

AbstractBackgroundThe comparability of thyroid-stimulating hormone (TSH) results cannot be easily obtained using SI-traceable reference measurement procedures (RPMs) or reference materials, whilst harmonization is more feasible. The aim of this study was to identify and validate a new approach for the harmonization of TSH results.MethodsPercentile normalization was applied to 125,419 TSH results, obtained from seven laboratories using three immunoassays (Access 3rd IS Thyrotropin, Beckman Coulter Diagnostics; Architect System, Abbott Diagnostics and Elecsys, Roche Diagnostics). Recalibration equations (RCAL) were derived by robust regressions using bootstrapped distribution. Two datasets, the first of 119 EQAs, the second of 610, 638 and 639 results from Access, Architect and Elecsys TSH results, respectively, were used to validate RCAL. A dataset of 142,821 TSH values was used to derive reference intervals (RIs) after applying RCAL.ResultsAccess, Abbott and Elecsys TSH distributions were significantly different (p < 0.001). RCAL intercepts and slopes were −0.003 and 0.984 for Access, 0.032 and 1.041 for Architect, −0.031 and 1.003 for Elecsys, respectively. Validation using EQAs showed that before and after RCAL, the coefficients of variation (CVs) or among-assay results decreased from 10.72% to 8.16%. The second validation dataset was used to test RCALs. The median of between-assay differences ranged from −0.0053 to 0.1955 mIU/L of TSH. Elecsys recalibrated to Access (and vice-versa) showed non-significant difference. TSH RI after RCAL resulted in 0.37–5.11 mIU/L overall, 0.49–4.96 mIU/L for females and 0.40–4.92 mIU/L for males. A significant difference across age classes was identified.ConclusionsPercentile normalization and robust regression are valuable tools for deriving RCALs and harmonizing TSH values.

scholarly journals Decrease of Free Thyroxine Levels after Controlled Ovarian Hyperstimulation1

2000 ◽  
Vol 85 (2) ◽  
pp. 545-548 ◽  
Author(s):  
A. F. Muller ◽  
A. Verhoeff ◽  
M. J. Mantel ◽  
F. H. de Jong ◽  
A. Berghout
Keyword(s):  
Controlled Ovarian Hyperstimulation ◽  
Thyroid Stimulating Hormone ◽  
Psychomotor Development ◽  
Ovarian Hyperstimulation ◽  
Free T4 ◽  
Before And After ◽  
Maternal Thyroid ◽  
A Prospective Study ◽  
Opposing Effects ◽  
Stimulating Hormone

Controlled ovarian hyperstimulation could lead to opposing effects on thyroid function. Therefore, in a prospective study of 65 women undergoing controlled ovarian hyperstimulation, thyroid hormones, T4-binding globulin, TPO antibodies, gonadotropins, estradiol, and PRL were measured before and after controlled ovarian hyperstimulation. After ovarian stimulation (mean ± se of mean): free T4 decreased, 14.4 ± 0.2 vs. 12.9 ± 0.2 pmol/L (P &lt; 0.0001); thyroid-stimulating hormone increased, 2.3 ± 0.3 vs. 3.0 ± 0.4 mU/L (P &lt; 0.0001); T4-binding globulin increased, 25.2 ± 0.7 vs. 33.9 ± 0.9 mg/L (P &lt; 0.0001); total T4 increased, 98.1 ± 2.3 vs. 114.6 ± 2.5 nmol/L (P &lt; 0.0001); total T3 increased, 2.0 ± 0.04 vs. 2.3 ± 0.07 nmol/L (P &lt; 0.0001); TPO antibodies decreased, 370 ± 233 U/mL vs. 355 ± 224 U/mL (P &lt; 0.0001); LH decreased, 8.1 ± 1.1 vs. 0.4 ± 0.1 U/L (P &lt; 0.0001); FSH did not change, 6.5± 0.6 vs. 7.9 ± 0.9 U/L (P = 0.08); human CG increased, &lt;2 ± 0.0 vs. 195 ± 16 U/L (P &lt; 0.0001); estradiol increased, 359.3 ± 25.9 pmol/L vs. 3491.8 ± 298.3 pmol/L (P &lt; 0.0001); and PRL increased, 0.23 ± 0.02 vs. 0.95 ± 0.06 U/L (P &lt; 0.0001). Because low maternal free T4 and elevated maternal thyroid-stimulating hormone levels during early gestation have been reported to be associated with impaired psychomotor development in the offspring, our findings indicate the need for additional studies in the children of women who where exposed to high levels of estrogens around the time of conception.

scholarly journals The effect of iodine in patients using povidone-iodine mouth wash on thyroid function

2019 ◽  
Vol 5 (6) ◽  
pp. 1562 ◽  
Author(s):  
Gowri Shankar Murugesan ◽  
Manju Priya Venkat
Keyword(s):  
Thyroid Gland ◽  
Thyroid Function ◽  
Povidone Iodine ◽  
Endocrine System ◽  
Thyroid Stimulating Hormone ◽  
Increased Risk ◽  
Before And After ◽  
Mouth Wash ◽  
Serum Tsh ◽  
Stimulating Hormone

<p class="abstract"><strong>Background:</strong> Thyroid gland is a key part of endocrine system and it performs its functions via two most important thyroid hormones thyroxine (T4) and triiodothyronine (T3). Thyroid gland is mainly regulated by thyroid-stimulating hormone (TSH). Povidone-iodine (polyvinylpyrrolidone-iodine, PVP-I) mouthwash is commonly used to treat infections of the oral cavity and oropharynx and iodine released from PVP-I can interfere with thyroid function. In this study the effect of brief treatment with povidone-iodine mouth wash on thyroid function was assessed. The aim of the present study was to assess whether iodine is absorbed through oral transmucosal route and interfere with TSH in serum.</p><p class="abstract"><strong>Methods:</strong> Fifty one patients with acute and chronic pharyngitis and tonsillitis were recruited and out of which forty-seven patients were treated with 20 ml of PVP-I mouthwash twice daily for 3 weeks and blood was collected from the respective patients before and after treatment with PVP-I. Serum thyroid stimulating hormone concentration was measured from the collected blood samples of the patients.</p><p class="abstract"><strong>Results:</strong> In the present study there was a small increase in serum TSH concentration during the therapy with PVP-I but the concentration determined was within the normal range.</p><p class="abstract"><strong>Conclusions:</strong> Based on the results of this study we conclude that the use of PVP-I for a brief period transiently increase TSH value and prolonged use should be avoided in people with an increased risk of thyroid dysfunction and other autoimmune disorders.</p>

scholarly journals Parameters affecting the period for being euthyroid in newly-diagnosed Graves’ disease treated with antithyroid agent

2020 ◽  
Vol 8 (9) ◽  
pp. 3165
Author(s):  
Iskender Ekinci ◽  
Hande Peynirci
Keyword(s):  
Thyroid Function ◽  
Smoking Status ◽  
Antithyroid Drug ◽  
Thyroid Stimulating Hormone ◽  
Graves Disease ◽  
Thyroid Function Tests ◽  
Newly Diagnosed ◽  
Function Tests ◽  
Significant Difference ◽  
Stimulating Hormone

Background: There are limited data about the factors affecting the response time to medical treatment in Graves’ disease (GD) although many studies examined the predictors of the relapse after drug withdrawal. The aim of the current study was to evaluate the time for becoming euthyroid under antithyroid drug (ATD) therapy and the parameters influencing this period in patients diagnosed as GD.Methods: Patients with newly-diagnosed GD and decided to treat with ATD initially between March 2017 and September 2018 were retrieved retrospectively. Sociodemographic features as well as laboratory parameters like thyroid function tests and thyroid-stimulating hormone-receptor antibody (TRab) at the time of diagnosis were recorded.Results: Out of 41 patients, 63.4% (n=26) were female. The mean age was 36.1±11.7 years and 43.9% (n=18) of them were smoking. The time between the initiation of treatment and the duration of becoming euthyroid was 2.4±1.8 months. No significant difference was noted between age, gender, and smoking status and the time to become euthyroid under ATD treatment. This period was significantly positively correlated with levels of free triiodothyronine, free thyroxine, and negatively correlated with thyroid-stimulating hormone. Response to ATD therapy was higher in patients with pre-treatment TRab levels <10 IU/l than TRab ≥10 IU/l (p=0.011).Conclusions: Pretreatment thyroid function tests and TRab levels may be taken into consideration before deciding treatment in patients with newly diagnosed GD. It would be useful to design more comprehensive studies so that this proposal can find a response in clinical practice.

scholarly journals Association of Sub-Clinical Hypothyroidism with Abnormal Levels of Lipid in the Population of Nawabshah, Pakistan

2021 ◽  
pp. 452-458
Author(s):  
Nasrullah Aamer ◽  
Beenish Ghafar Memon ◽  
Abdul Rashid ◽  
Dayaram Makwana ◽  
Shahzad Memon ◽  
...  
Keyword(s):  
Subclinical Hypothyroidism ◽  
Thyroid Stimulating Hormone ◽  
Free Triiodothyronine ◽  
Cross Sectional ◽  
Significant Difference ◽  
Group A ◽  
The Mean ◽  
Group 2 ◽  
Group B ◽  
Stimulating Hormone

Aims: Aim of this investigation was to access the association of dyslipidemia with subclinical hypothyroidism. Methodology: In this cross-sectional investigation, 1948 participants were recruited. Two groups were made; participants up to 18 years were in group A and Subjects over 18 years were incorporated in group 2. They were subdivided into control, subclinical hypothyroid 1, and subclinical hypothyroid 2. SPSS 21 was used for data analysis. Results:  Data of 1619 individuals were analyzed. The mean age of Group A participants was 12.79 ± 2.779, and the mean age of Group B participants was 42.58 ± 18.012. The prevalence of subclinical hypothyroid was found at 13.5 %. Significant differences have been observed while comparing Group A and Group B (P <0.001). Free tetraiodothyronine and Free triiodothyronine also showed a significant difference in both groups. (P<0.05). No significant difference between mean Thyroid-stimulating hormone levels was observed (P>0.05). No significant association between Controls and High-density Lipid values was found between Controls and subclinical hypothyroid. Conclusion: We conclude that subclinical hypothyroidism leads to increased dyslipidemia. Lower Serum total cholesterol and low-density lipid levels were detected among children and participants under the age of 18 with Thyroid-stimulating hormone greater than 10 mIU/L. Thyroid-stimulating hormone less than 10.0 mIU/L had no lipid abnormalities in subclinical hypothyroid participants.

scholarly journals Clinical and Laboratory Evaluation between Serum Cholesterol and Thyroid Stimulating Hormone Level in the Patients of Thyroid Dysfunction and Hypothyroidism

2021 ◽  
Vol 11 (1) ◽  
pp. 3036-3048
Keyword(s):  
Serum Cholesterol ◽  
Thyroid Dysfunction ◽  
Density Lipoprotein ◽  
Thyroid Stimulating Hormone ◽  
Laboratory Evaluation ◽  
P Value ◽  
Cholesterol Levels ◽  
Significant Difference ◽  
Hypothyroid Patients ◽  
Stimulating Hormone

Thyroid hormones regulate lipid and lipoprotein metabolism; Therefore, thyroid dysfunction induces significant changes in lipid levels. This study was carried out to study the prevalence of thyroid disease and observe the association between hypothyroidism and serum cholesterol levels. A cross-sectional study enrolling all 50 diagnosed hypothyroid patients coming to the hospital lab irrespective of age and sex was selected, conducted during 2018-2020. The present study was conducted in the department of biochemistry in fifty hypothyroid male and female cases and 50 healthy controls. Serum triiodothyronine (T3), thyroxine (T4), thyroid-stimulating hormone (TSH), Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and Triglycerides were estimated in these patients, and the results were analyzed. Mean values of Serum Cholesterol in cases (<0.001), there was a significant difference between serum cholesterol of hypothyroid cases and controls with p-value <0.001. There was a significant difference between serum TSH of hypothyroid cases and controls with a p-value <0.000. We found that in other investigations FBS, TG, VLDL, T3 & T4, the p-value was found significant among cases and controls. In the present study, we concluded that TSH level is increased and T3 and T4 levels are decreased in hypothyroid patients, creatinine, and cholesterol levels are increased in hypothyroid patients. We observed that there is an increase in TSH levels as age increases. We can say that any change in thyroid hormone levels alters skeletal muscles' functioning and decreases renal perfusion and filtration capacity.

scholarly journals THE EFFECT OF ANTICONVULSANT DRUGS ON SERUM THYROID-STIMULATING HORMONE

2021 ◽  
pp. 144-146
Author(s):  
NEETHU T T ◽  
SYAM S ◽  
BEENA V ◽  
DHANYA S P
Keyword(s):  
Quality Of Life ◽  
Thyroid Function ◽  
Sodium Valproate ◽  
Thyroid Stimulating Hormone ◽  
Control Group ◽  
Significant Difference ◽  
Epileptic Patients ◽  
The Mean ◽  
Stimulating Hormone

Objective: Antiepileptic (AED) drugs are an integral component of the management of seizure disorder; however, they have a wide spectrum of adverse effects. It is important to be aware of these side effects as they have a major impact on the quality of life and are sometimes partially reversible after drug discontinuation. Among them, the influence of AED on thyroid function is an important one. However, there is only limited data available. The objective of this study is to evaluate the effect of AED on thyroid-stimulating hormone (TSH). Methods: A cross-sectional study of 1-year duration (march 2017 – march 2018) was conducted among 150 epileptic patients receiving phenytoin, carbamazepine, and sodium valproate for more than 6 months in a tertiary care center in central Kerala. Serum levels of TSH of patients on AED were compared with that of 50 healthy age- and sex-matched control groups. Data regarding the same were analyzed using SPSS version 16 with the Chi-square test, ANOVA, and independent t-test. Results: A total of 150 epileptic patients with a mean age of 35.54 + 10.72, including 66 males (44%) and 84 females (56%) were enrolled in this study. Fifty adults of mean age 36.5+ 8.4 and male to female ratio 1.10:1 formed the control group. It was found that the mean TSH value of patients on phenytoin (3.97+ 1.47), carbamazepine (3.57+ 1.44), and sodium valproate 3.03 + 1.41 significantly higher than that of the control group (1.91 + 0.72). On comparing the mean serum TSH of the drug group significant difference noted between phenytoin and sodium valproate treated group. Among the 12 patients develop subclinical hypothyroidism 65% taking drugs for more than 5 years. Conclusion: There is a positive correlation between the use of anticonvulsants and thyroid dysfunction and the association increases with the duration of therapy. The clinicians should be encouraged for regular monitoring of thyroid function test to impart a better quality of life to the patients.

scholarly journals Evaluation of SNA001, a Novel Recombinant Human Thyroid Stimulating Hormone Injection, in Patients With Differentiated Thyroid Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Yushen Gu ◽  
Hongrong Xu ◽  
Yanling Yang ◽  
Yan Xiu ◽  
Pengcheng Hu ◽  
...  
Keyword(s):  
Adverse Events ◽  
Thyroid Carcinoma ◽  
Gastrointestinal Symptoms ◽  
Thyroid Stimulating Hormone ◽  
Whole Body ◽  
Human Thyroid ◽  
Dependent Manner ◽  
Significant Difference ◽  
Iodine 131 ◽  
Stimulating Hormone

SNA001 is a novel recombinant human thyroid stimulating hormone (rhTSH). rhTSH has long been approved in several countries to facilitate monitoring and ablation of thyroid carcinoma without hypothyroidism caused by thyroid hormone withdrawal (THW). To assess the safety, tolerance, pharmacokinetic and pharmacodynamic properties of SNA001, the two-period (SNA001 period and THW period), dose-ascending study in well-differentiated thyroid cancer (DTC) patients was designed. Three doses (0.45 mg, 0.9 mg, and 1.35 mg) of SNA001 were intramuscularly injected, twice in the SNA001 period to stimulate iodine-131 uptake and thyroglobulin (Tg) release. 24 h after the last dose of SNA001, iodine-131 (111–185 MBq) was administrated, followed by whole-body scan (WBS) 48 h later. THW period began just after SNA001 washout and lasted for about 3–6 weeks. When TSH level was above 30 mU/L, iodine-131 (111–185 MBq) was administrated, followed by a WBS and Tg detection 48 h later. Twenty-four DTC patients after thyroidectomy were enrolled; mean peak concentrations of SNA001 in 0.45, 0.9, and 1.35 mg groups were 18.5, 26.7, and 37.0 ng/ml (about 244.7, 354.2, and 489.6 mU/L) respectively, within 28–32 h after first dose of SNA001. SNA001 was metabolized in a dose-dependent manner. The results of WBS and Tg release in the SNA001 period were compared with those in the THW period. Compared to Tg level in baseline, the Tg levels in SNA001 and THW periods were increased, with 78% of subjects showing higher Tg levels in the THW period. 100% of the patients had concordant qualitative results of the scans within two periods in three groups. Symptoms of hypothyroidism were relieved in the SNA001 period compared with THW period, though there was no significant difference in most of the scale scores. There were no serious adverse events related to SNA001; the most common adverse events were gastrointestinal symptoms of mild and transient nature. Thus, SNA001 promises to be a safe and effective method to stimulate iodine-131 uptake and Tg secretion during monitoring and ablation for DTC without the disadvantages of incidental hypothyroidism.

Sign in / Sign up

Export Citation Format

Share Document